HQY HEALTHEQUITY, INC.
Services-Business Services, NEC · Nasdaq · SEC CIK 1428336 · Fiscal year ends 01/31
Financial factors as of 2026-07-31 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.3%
TTM net income YoY62.2%
TTM EPS YoY67.9%
Revenue 3-yr CAGR13.2%
Net income 3-yr CAGR164.2%
Margins
Gross margin71.2%
Operating margin25.8%
Net margin17.4%
FCF margin35.8%
EBITDA margin31.5%
Returns
ROE11.4%
ROA7.1%
ROIC (approx.)9.8%
Asset turnover0.41x
Leverage & solvency
Liabilities / assets39.2%
Debt / equity0.47x
Current ratio2.99x
Interest coverage6.69x
Cash quality & payout
Operating cash flow / net income2.07x
Accruals ratio-7.6%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-01-31 | FY20252025-01-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.31B | $1.20B |
| Cost of revenue | $400.31M | $422.51M |
| Gross profit | $913.12M | $777.26M |
| R&D expense | $262.51M | $239.51M |
| SG&A expense | $119.93M | $132.26M |
| Operating income | $322.46M | $162.33M |
| Interest expense | $57.13M | $60.63M |
| Pretax income | $277.43M | $116.03M |
| Income tax | $62.23M | $19.33M |
| Net income | $215.20M | $96.70M |
| EBITDA | $477.11M | $324.79M |
| EPS (basic) | 2.50 | 1.11 |
| EPS (diluted) | 2.46 | 1.09 |
| Weighted avg. shares (diluted) | 87.47M | 88.83M |
| Balance sheet | ||
| Cash & equivalents | $318.93M | $295.95M |
| Receivables | $123.70M | $118.01M |
| Current assets | $512.28M | $477.75M |
| PP&E, net | $3.18M | $3.24M |
| Goodwill | $1.65B | $1.65B |
| Intangibles | $1.10B | $1.20B |
| Total assets | $3.38B | $3.45B |
| Current liabilities | $156.85M | $156.32M |
| Short-term debt | $0 | $0 |
| Long-term debt | $957.38M | $1.06B |
| Total debt | $957.38M | $1.06B |
| Total liabilities | $1.27B | $1.33B |
| Shareholders' equity | $2.11B | $2.11B |
| Net debt | $638.45M | $760.35M |
| Shares outstanding | 85.01M | 86.54M |
| Cash flow statement | ||
| Operating cash flow | $457.09M | $339.86M |
| Capital expenditure | $1.97M | $2.08M |
| Free cash flow | $455.12M | $337.77M |
| Investing cash flow | -$47.14M | -$505.45M |
| Financing cash flow | -$386.98M | $57.57M |
| Depreciation & amortization | $154.66M | $162.45M |
| Stock-based compensation | $73.06M | $96.42M |
| Share buybacks | $299.25M | $121.49M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.